Prostate cancer

Researchers are testing a new cell therapy called CRTKVA11-03 in people with advanced solid tumors that carry a specific KRAS G12V mutation and a matching immune marker called HLA-A*11:01. The treatment uses each patient's own T cells, engineered to recognize and attack cancer ce…

Researchers are testing a combination of two radiation techniques for men with intermediate or high risk prostate cancer. Participants receive a shortened course of external beam radiation followed by a single high-dose brachytherapy boost, with optional hormone therapy. The tria…

Researchers in Denmark are testing a targeted radiation technique called focal brachytherapy for men with early prostate cancer. The treatment places radioactive sources directly into the tumor, guided by MRI and ultrasound, to destroy cancer while leaving the rest of the prostat…

Researchers are testing a robotic approach to remove the prostate through the perineum, the area between the scrotum and anus, in men with localized prostate cancer. The study aims to see if the procedure can be completed safely and effectively using the GelPOINT device and a rob…

This phase 1 trial tests an investigational DNA vaccine called pING-hHER3FL in people whose solid tumors have been surgically removed. The vaccine carries the genetic code for the HER3 protein, which is found on many cancer types, and aims to trigger a targeted immune response ag…

This early-phase study tests a personalized vaccine made from a patient's own immune cells and tumor markers. It aims to help the immune system attack advanced prostate cancer that has stopped responding to standard treatments. About 9 to 18 men will receive four doses over eight…

This early-stage study tests a personalized vaccine (PGV001) combined with an immune booster (CDX-301) in 27 men who have had aggressive prostate cancer but currently show no signs of tumor. The goal is to see if the vaccine is safe and can train the immune system to recognize an…

This study tests a combination of three drugs—radium-223, M3814, and avelumab—in men with advanced prostate cancer that no longer responds to hormone therapy and has spread to the bone. The goal is to see if the combination can slow cancer growth better than radium-223 alone. The…

This early-stage study tests a new drug called JSB462 (Luxdegalutamide) in 15 Japanese men whose prostate cancer has spread to other parts of the body. The main goal is to check the drug's safety and how the body processes it. Participants take the drug once daily with food.

This early-stage trial tests a personalized cell therapy (TIL injection) for people with advanced solid tumors that have spread or come back. The treatment uses the patient's own immune cells, grown in a lab, to fight the cancer. The main goal is to check safety, and the study wi…

This study tests a new drug, JSB462, combined with standard therapy (abiraterone) in 150 men whose prostate cancer has spread but still responds to hormone treatment. The goal is to see if the combination lowers PSA levels more effectively and delays cancer growth. Participants w…

This Phase II trial tests a new drug, JSB462 (luxdegalutamide), combined with a radioactive therapy (Pluvicto) in 138 men with PSMA-positive metastatic castration-resistant prostate cancer that has progressed after prior treatments. The study aims to see if the combination works …

This study tests whether a precise, short-course radiation method (SBRT) works as well as a slightly longer radiation approach (hypofractionated radiotherapy) for men whose prostate cancer has come back or spread to a few spots after surgery. About 118 participants will receive o…

This early-stage trial tests a new drug called denikitug, alone or with another drug (zimberelimab), in 416 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drugs shrink tumors…

This study tests whether a shorter, more intense radiation treatment (5 sessions) is better than the standard 20-session approach for men with intermediate- or high-risk prostate cancer that hasn't spread. The goal is to improve cancer control while keeping side effects low. Abou…

Researchers are testing a new drug called FOR46, which seeks out a protein called CD46 on cancer cells, together with enzalutamide, a standard hormone therapy, in men whose prostate cancer has spread and worsened despite prior treatment with abiraterone. The trial aims to find th…

This early-stage trial is testing an experimental drug called belzutifan in people with advanced solid tumors that have not responded to standard treatments. Belzutifan works by blocking a protein (HIF-2α) that tumors use to survive in low-oxygen conditions. The main goal is to f…

This study tests a procedure called TULSA that uses MRI images to guide high-energy ultrasound waves to destroy prostate cancer tumors. About 21 adults with early-stage prostate cancer that shows up on MRI will receive this heat-based treatment. The goal is to see if the approach…

This study tests three drugs—durvalumab (an immunotherapy), olaparib (a DNA repair blocker), and cediranib (a blood vessel growth blocker)—in different combinations for people with advanced solid tumors, especially ovarian cancer. The phase 1 part finds safe doses, and the phase …

This phase 3 study tested whether adding enzalutamide (Xtandi) to standard hormone therapy (ADT) helps Chinese men with metastatic hormone-sensitive prostate cancer. 180 participants received either enzalutamide plus ADT or a placebo plus ADT. The main goal was to see how long it…

This study tests a drug called erdafitinib in people whose cancers have extra copies of the FGFR gene. The drug blocks a faulty protein that helps cancer grow. Researchers want to see if it can shrink tumors or stop them from getting worse. About 35 adults with advanced or hard-t…

This study tests a combination of two drugs—cabazitaxel (a chemotherapy) and enzalutamide (a hormone blocker)—in people with prostate cancer that has spread and stopped responding to standard hormone therapy. The goal is to find the safest dose and see if the combination can lowe…

This phase 1 trial is testing the safety and best dose of a combination of three drugs—entinostat, nivolumab, and ipilimumab—in people with advanced solid tumors that have spread or cannot be removed. The goal is to see if this mix can help the immune system fight cancer more eff…

This study is the first time BNT314 is being tested in humans. It aims to see if the drug is safe for people with advanced solid tumors that have not responded to other treatments. About 41 participants will receive different doses to find the highest dose that is still safe and …

This study tests whether adding the immune-boosting drug Sipuleucel-T (Provenge) to standard hormone therapy can help men with advanced prostate cancer that is no longer responding to hormones alone. The trial involves 26 participants who will receive either Sipuleucel-T alone or…

This phase 2 trial is testing the drug osimertinib in 19 patients with advanced cancers (like lymphoma or solid tumors) that have specific EGFR mutations. Osimertinib is a pill that blocks the faulty EGFR protein, which can help stop tumor growth. The study aims to see if the dru…

This early-phase trial tested the safety and best dose of two drugs—riluzole and sorafenib—given together to people with advanced solid tumors or melanoma that had spread and stopped responding to standard treatments. The goal was to find the highest safe dose and see if the comb…

Researchers are testing an experimental oral drug called PhOx430 in people with advanced solid tumors, including glioblastoma and triple-negative breast cancer. The trial has two parts: first, they give increasing doses to small groups to find a safe dose and watch for side effec…

Researchers are testing an experimental antibody called ONC-392 in people with advanced solid tumors, including non-small cell lung cancer and melanoma. The trial gives ONC-392 alone or with pembrolizumab, an approved immunotherapy, to see what doses are safe and how the body pro…

This study tests whether a one-time procedure called brachytherapy, where tiny radioactive seeds are placed directly into the prostate, can control intermediate risk prostate cancer without needing additional treatments. Three hundred men with specific tumor features (Gleason sco…

This study tested a combination of two drugs, veliparib and topotecan, in 88 patients with solid tumors or ovarian cancer that returned after initial treatment. The goal was to find the safest dose and see how well the drugs shrink tumors. While the treatment aims to control the …

This phase 3 trial is testing whether adding the drug niraparib to standard therapy (abiraterone and prednisone) can slow cancer growth in men with metastatic castration-sensitive prostate cancer who have specific inherited or tumor gene mutations. About 700 participants are bein…

This study tests different combinations of approved drugs in 196 men with advanced prostate cancer that has spread and no longer responds to hormone therapy. The goal is to see which combinations work best to extend life and control the cancer. Participants receive standard hormo…

This study looked at 612 men with prostate cancer that had been removed by surgery. It compared standard treatment (hormone therapy plus radiation) against the same treatment plus the chemotherapy drug docetaxel. The goal was to see if adding chemo helps keep the cancer from comi…

Men with prostate cancer often receive androgen deprivation therapy, which can raise the risk of heart problems and metabolic issues. This trial tests whether adding semaglutide, a GLP-1 receptor agonist, can control cardiovascular risk factors like weight, blood pressure, and ch…

This study tests a gel called SpaceIT that is placed between the prostate and rectum before radiation therapy for prostate cancer. The gel acts as a spacer to reduce radiation reaching the rectum, potentially lowering side effects. About 230 adults with low- to intermediate-risk …

This study looks at the long-term safety of the drug enzalutamide in people with prostate cancer who have already been taking it in a previous study and are still benefiting. About 900 participants will continue their current treatment and be monitored for side effects. The goal …

This phase 3 trial tests a radioactive drug called 177Lu-PSMA-617 in 469 men with advanced prostate cancer that has stopped responding to hormone therapy. The drug seeks out and delivers radiation directly to cancer cells. Researchers compare it to switching to another hormone th…

This early-phase study tests a new drug, RO7247669, that targets two immune system checkpoints (PD-1 and LAG-3) to help the body fight cancer. About 170 adults with advanced solid tumors (including melanoma, lung cancer, and esophageal cancer) who have run out of standard options…

This study tests a radioactive drug (lutetium-177) alone or combined with newer hormone therapy in 49 men with a specific type of prostate cancer that has stopped responding to standard hormone therapy but hasn't spread on regular scans. The goal is to see if the treatment can lo…

This study tests a new radioactive drug, 225Ac-PSMA-R2, in men with advanced prostate cancer that has spread and is no longer responding to standard treatments. The drug is designed to seek out and destroy cancer cells that have a specific marker called PSMA. The trial will check…

This early-phase trial is testing an experimental drug called TTX-080, which blocks a protein (HLA-G) that tumors use to hide from the immune system. The study will give TTX-080 alone or combined with other cancer drugs (pembrolizumab, cetuximab, or FOLFIRI plus cetuximab) to abo…

This study tests whether a new drug (BMS986365) combined with hormone therapy (degarelix) can safely shrink or eliminate high-risk prostate cancer before standard surgery. About 30 participants will receive the combination for several months, then have their prostate removed. The…

This early-stage trial tested the safety and best dose of two drugs, ixabepilone and temsirolimus, given together to adults with advanced solid tumors that had spread or could not be removed. The goal was to find a dose that limits side effects while potentially killing more canc…

This study tests an experimental drug called TransCon IL-2 β/γ, which aims to boost the immune system to fight cancer. It is given alone or with other treatments like pembrolizumab (Keytruda) or chemotherapy. The trial includes 320 adults with advanced solid tumors that have not …

This study tests whether adding capivasertib to standard hormone therapy (abiraterone plus prednisone and ADT) can slow cancer growth better than standard therapy alone. It includes about 1,000 men with newly diagnosed, hormone-sensitive prostate cancer that has spread and has a …

This early-phase trial tests a new drug called BAY 1895344 combined with standard chemotherapy (irinotecan or topotecan) in people with advanced solid tumors, especially small cell lung cancer, poorly differentiated neuroendocrine cancer, and pancreatic cancer. The goal is to fin…

This early-stage study tests a new drug called GEN1042, which aims to help the immune system fight cancer. It is being tested alone or with other cancer drugs in 42 Japanese adults with advanced solid tumors. The main goal is to check safety and find the right dose.

This early-phase trial tested two oral drugs, cediranib and selumetinib, in 19 people with advanced solid tumors (including melanoma) that had stopped responding to standard treatments. Cediranib works by cutting off blood supply to tumors, while selumetinib blocks a key growth s…

This early-phase trial tests two drugs together—MK-2206 and hydroxychloroquine—in people with advanced solid tumors, melanoma, kidney, or prostate cancer. The goal is to find the safest dose and see how the combination affects cancer cell growth. About 62 participants will take b…

This study looks at whether a special gene test can help men with low-risk prostate cancer decide to monitor their cancer instead of treating it right away. About 805 men with early-stage prostate cancer will be randomly assigned to have the gene test or not. The goal is to see i…

This phase I trial tests the drug pazopanib (Votrient) in 54 patients with advanced solid tumors that have spread or not responded to other treatments. Pazopanib works by blocking blood vessel growth that tumors need. Researchers aim to find the best dose that balances effectiven…

This early-phase study tests a new drug called M9466, a PARP1 inhibitor, alone or combined with other drugs in 60 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and how the body processes the drug. Researchers …

This phase 2 trial tests a multi-drug approach for men with aggressive variant prostate cancer that has spread. First, patients receive chemotherapy (cabazitaxel and carboplatin) plus an immunotherapy (cetrelimab). Then, they are randomly assigned to take either a PARP inhibitor …

This study tests a drug called olaparib in people with advanced cancers (like brain tumors, bile duct cancer, or other solid tumors) that have a specific gene change called IDH1 or IDH2 mutation. The drug works by blocking an enzyme that cancer cells need to grow. About 89 partic…

This study tests a combination of two drugs—olaparib and radium-223—in men with castration-resistant prostate cancer that has spread to bone. Olaparib blocks a protein that helps cancer cells repair themselves, while radium-223 delivers radiation directly to bone tumors. The tria…

This Phase 3 trial tests whether adding talazoparib to enzalutamide can slow the spread of metastatic castration-resistant prostate cancer (mCRPC). About 1,054 men with this advanced cancer are taking either the drug combo or a placebo plus enzalutamide. The study tracks how long…

This phase 3 trial compares a new drug, BMS-986365, against standard treatments (docetaxel or other hormone therapies) in 960 men with metastatic castration-resistant prostate cancer that has stopped responding to hormone therapy. The main goal is to see if the new drug delays ca…

This phase 2 trial is testing a combination of two drugs—cabozantinib (a pill) and nivolumab (an infusion)—in 47 men with metastatic castration-resistant prostate cancer, a type that has stopped responding to hormone therapy. The main goal is to see if the treatment can delay can…

This early-phase study tests an experimental oral drug (E7727) combined with another oral drug (decitabine) in people with advanced solid tumors that have not responded to at least two prior treatments. The main goals are to find the safest dose and understand side effects. Up to…

This phase III trial tests whether a smartphone app called Quit2Heal can help cancer patients stop smoking better than the standard QuitGuide app. The study involves 427 adults with cancer who smoke and are interested in quitting. Participants use one of the two apps to get suppo…

This study is testing a new drug called xaluritamig in men whose prostate cancer has returned after initial treatment but has not spread. The main goal is to see if the drug is safe and tolerable. About 50 participants will receive the drug, and researchers will monitor side effe…

This phase 3 trial is testing whether a new type of targeted radiation therapy, called 177Lu-PSMA-I&T, can slow the progression of metastatic castration-resistant prostate cancer better than standard hormone therapy. The study enrolls men with prostate cancer that has spread and …

This early-stage trial tests a new drug called ICT01, a lab-made antibody, in 292 people with advanced cancers that have not responded to standard treatments. The drug is given alone or with another cancer drug (Keytruda). The main goals are to check safety and see if the drug ca…

This Phase 3 trial tests whether adding talazoparib (a targeted drug) to standard hormone therapy (enzalutamide) works better than hormone therapy alone for men with metastatic prostate cancer that has a specific DNA repair mutation. About 600 men are participating. The study mea…

This phase II trial tests whether green tea catechins (GTC) can prevent low-risk prostate cancer from progressing in men on active surveillance. 360 participants will receive either GTC or a placebo daily. The study measures changes in a tumor growth marker (Ki-67) in biopsy samp…

This phase II trial tests whether giving cancer drugs based on a tumor's genetic makeup can help people with advanced solid tumors that cannot be removed by surgery or have spread. About 920 participants will receive a drug or drug combination tailored to their tumor's specific g…

This trial tests whether giving a lower dose of radiation in just two sessions can reduce urinary side effects for men with intermediate-risk prostate cancer. All participants receive radiation on an MR-Linac, a machine that combines MRI imaging with radiotherapy for precise targ…

This study tests a new treatment called AB-3028, which uses a patient's own immune cells (T cells) that have been modified in a lab to better attack prostate cancer cells. It is for men with metastatic castration-resistant prostate cancer, a type that has stopped responding to ho…

This study tests a drug called trastuzumab deruxtecan, alone or with other medicines, in people with advanced solid tumors that have a protein called HER2. The goal is to see if the drug can shrink or control these cancers. About 127 adults with tumors that cannot be removed by s…

This study tests a new drug combination (FPI-2265 and olaparib) in 85 men with advanced prostate cancer that no longer responds to standard hormone therapy. The goal is to see if the treatment can shrink tumors or lower PSA levels by at least 50%. Participants must have tried at …

This study tests an experimental drug called LM-108, given alone or with another immunotherapy (toripalimab), in people with advanced solid tumors that have stopped responding to standard treatments. The trial has two phases: first, finding the safest dose, then expanding to see …

This early-stage trial tests an experimental mRNA-based cancer vaccine (mRNA-4157) in 161 people with solid tumors. The vaccine is designed to train the immune system to attack cancer cells. Some participants receive the vaccine alone, while others get it with the immunotherapy d…

This trial tests whether two different PET/CT tracers—fluciclovine F18 and 68Ga-PSMA—can better guide radiation therapy planning for men with prostate cancer who have a rising PSA after surgery. The goal is to see if one tracer more accurately spots remaining cancer cells, allowi…

This early-stage trial is testing a new drug, saruparib, in 41 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, how it interacts with other common medications, and how well different pill versions wor…

This phase II study tests whether giving an extra-high radiation dose directly to the main prostate tumor, while treating the rest of the prostate with standard SBRT, can reduce the chance of cancer coming back. About 91 men with intermediate-risk prostate cancer will receive fiv…

This early-phase study tests whether a diet very low in vitamin B6 can make immunotherapy work better for people with solid tumors. About 20 adults aged 18-80 will follow this special diet for 6 weeks while continuing their regular immunotherapy. The main goal is to check if the …

This early-stage trial tests FF-10850, a liposome-wrapped version of the chemotherapy drug topotecan, in 96 adults with advanced solid tumors like ovarian, cervical, and Merkel cell carcinoma. The main goals are to find the safest dose and understand side effects. Researchers hop…

This phase 1 trial tests FF-10832, a liposomal version of the chemotherapy drug gemcitabine, in adults with advanced solid tumors, including biliary tract cancer, that have not responded to standard treatment or have no standard options. Researchers give the drug as an intravenou…

This early-phase study tests a new drug called MK-2870, either alone or with the immunotherapy pembrolizumab, in Japanese patients with advanced solid tumors or a type of lung cancer. The main goal is to check the safety and side effects of these treatments. About 30 people will …

This phase 1 trial tests whether combining several investigational immunotherapy drugs, with or without chemotherapy, can safely shrink advanced solid tumors. The study enrolls adults with cancers like non-small-cell lung cancer or triple-negative breast cancer that have progress…

This phase I/II trial tests a combination of two drugs given directly into the spinal fluid for people with leptomeningeal metastasis, a condition where cancer spreads to the membranes covering the brain and spinal cord. The drugs are QL1706, a bispecific antibody that blocks two…

This study tests a drug called larotrectinib in 35 adults with advanced cancers (including lymphoma and solid tumors) that have a specific NTRK gene fusion. The drug blocks a faulty protein that tells cancer cells to grow, aiming to shrink tumors or stop them from spreading. Part…

This trial tests whether high-dose radiation aimed at a few cancer spots can slow the disease in men with prostate cancer that has stopped responding to hormone therapy. Half the participants receive radiation to their metastases, while the other half are watched without immediat…

This study tests the drug tarlatamab in people with advanced tumors that have a protein called DLL3. The goal is to see if the drug can shrink or control these tumors. About 29 adults with stage IV cancer will receive tarlatamab, and researchers will track how well it works and a…

This study looks at the long-term safety of brigimadlin, a cancer drug taken as tablets, in adults with solid tumours who have already received at least 4 cycles of it in a previous study. About 90 participants will take the drug once every 3 weeks, and doctors will monitor their…

This trial tests an experimental drug called CS5001, designed to seek out and destroy cancer cells that carry a specific marker (ROR1). It is being studied in people with advanced solid tumors or lymphomas that have progressed after standard treatments. The study will first find …

This early-phase study tests a new experimental drug (BI 770371) alone or with another immunotherapy (ezabenlimab) in adults with advanced solid tumors who have run out of standard options. The main goal is to find a safe dose and check for side effects. Up to 36 participants wil…

This study looks at whether men whose metastatic prostate cancer has responded very well to hormone therapy can safely pause treatment. About 79 men will stop their medications under doctor guidance to see if their testosterone levels recover and they remain cancer-free for at le…

This study tests a clinic program called ActivityChoice that helps cancer survivors become more physically active to lower their risk of heart disease. About 114 adult cancer survivors will be offered a choice of group in-person, group virtual, or self-monitored digital exercise …

This study tests a special scaffold placed during prostate removal surgery to help men regain bladder control. About 266 men will be randomly assigned to get the scaffold or standard care. The goal is to see if the scaffold reduces urine leakage and improves quality of life over …

This trial tests whether adding metformin, a common diabetes drug, to standard hormone therapy can delay cancer progression in men with newly diagnosed metastatic hormone-sensitive prostate cancer. Half the participants receive metformin alongside androgen deprivation therapy (AD…

This early-phase trial is testing an experimental drug called AB598, alone or with other cancer drugs, in 40 people with advanced solid tumors like lung, bladder, or breast cancer. The main goal is to check safety and find the right dose. It is not yet known if the drug helps shr…

This study tested a drug called apalutamide in over 1,200 men with a type of prostate cancer that has stopped responding to hormone therapy but has not yet spread. The goal was to see if the drug could delay the cancer from spreading to bones or other organs. Participants took ei…

This study tests a new drug called Cetrelimab (JNJ-63723283) in 234 people with advanced solid tumors like lung, melanoma, bladder, and colorectal cancers. The drug works by blocking PD-1, a protein that stops the immune system from attacking cancer cells. The trial has two parts…

This phase 3 trial tests whether adding apalutamide (a daily pill) to standard hormone therapy helps men with metastatic hormone-sensitive prostate cancer live longer and delay disease progression. Over 1,000 participants received either apalutamide plus hormone therapy or a plac…

This phase 3 trial tests whether adding apalutamide to standard treatment (abiraterone and prednisone) can delay cancer growth in men with advanced prostate cancer that no longer responds to hormone therapy. About 982 participants who have not had chemotherapy are randomly assign…

This early-stage trial tests a new drug called ARX517, which is designed to find and kill prostate cancer cells while sparing healthy ones. It is being tested alone or with other standard treatments in 183 men with prostate cancer that has spread to other parts of the body. The m…

This study tests an experimental drug called CTL-002, given alone or with an approved immunotherapy, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find a safe dose and see if the combination can shrink tumors or slow thei…

This study tests an experimental drug called AZD5305, a PARP inhibitor, either alone or combined with other cancer drugs in people with advanced solid tumors (like ovarian, breast, pancreatic, and lung cancers). The goal is to see if the treatment is safe and can shrink tumors. A…

This study tests whether robot-assisted removal of the prostate, along with lymph node dissection, can help control cancer in men with oligometastatic hormone-sensitive prostate cancer—cancer that has spread to a few spots in the spine or pelvis. Participants have been on hormone…

This trial is testing an experimental oral drug called ODM-208 in men with metastatic castration-resistant prostate cancer, a type of prostate cancer that has spread and no longer responds to standard hormone therapy. The main goal is to find the highest safe dose and to assess t…

This study tests whether a higher dose of proton radiation, focused on tumors seen on MRI, can better control high-risk prostate cancer. About 100 participants will receive radiation over 8-9 weeks, plus hormone therapy for 18 months. The goal is to lower the chance of cancer ret…

This study tests whether adding the drug abemaciclib to standard treatment (abiraterone acetate plus prednisone) can help men with metastatic castration-resistant prostate cancer live longer without their cancer getting worse. About 393 participants will receive either the combin…

This trial tests whether a focal treatment called irreversible electroporation (IRE) can control localized prostate cancer as effectively as radical treatments, but with fewer side effects. IRE uses high-voltage electrical pulses to destroy tumor cells while sparing surrounding h…

This phase 3 trial is testing whether giving the chemotherapy drug docetaxel more often but at a lower dose—every 2 weeks instead of every 3 weeks—can reduce severe side effects in men with metastatic hormone-sensitive prostate cancer. All participants also receive the standard c…

This early-stage trial is testing an experimental oral drug, TYRA-200, in people with advanced bile duct cancer (intrahepatic cholangiocarcinoma) and other solid tumors that have specific changes in the FGFR2 gene. The study aims to find a safe and effective dose and to see wheth…

This phase 3 trial tests whether focused high-intensity ultrasound (HIFU) can destroy low-risk prostate tumors without the side effects of radical treatments. Men aged 50-80 with a single, low-risk tumor will be randomly assigned to either HIFU or active surveillance (regular mon…

This trial compares two ways of delivering radiation to the pelvis in men with unfavorable intermediate- or high-risk prostate cancer. One group receives the standard 25 sessions of radiation, while the other receives just 5 sessions with a higher dose per session. The goal is to…

This early-phase trial tests a combination of three drugs—copanlisib, olaparib, and durvalumab—in people with advanced solid tumors that have spread or can't be removed by surgery. The goal is to find the safest dose and see if the drugs work together to shrink tumors. Only patie…

This Phase 3 trial tests whether adding the experimental drug saruparib to standard hormone therapy can slow cancer growth in men with metastatic prostate cancer that still responds to hormone treatment. About 1,889 men will receive either saruparib or a placebo, plus a hormone d…

This study tests a new approach for men with intermediate-risk prostate cancer. First, doctors use electric pulses (IRE) to destroy tumor cells, followed by precise radiation (MRgRT). The goal is to see if this combination is safe and can keep cancer away for at least a year. Abo…

This trial tests whether analyzing a child's DNA before prescribing supportive care drugs can lower the risk of serious side effects. Children with cancer or those receiving a bone marrow transplant are randomly assigned to get either standard care or prescribing guided by their …

This trial investigates whether real-time motion management techniques—like triggered imaging and MLC tracking—can safely reduce the target margins used during radiotherapy for prostate and lung cancer. By adjusting the radiation beam to follow tumor movement, researchers aim to …

This early-stage trial tests a new drug called PSW-1025, which delivers a radioactive particle (astatine-211) directly to prostate cancer cells. The goal is to see if this targeted approach is safe and tolerable for men with castration-resistant prostate cancer, a form that no lo…

This study offers continued treatment with atezolizumab (Tecentriq) to about 1,000 cancer patients who were already benefiting from it in earlier Roche-sponsored trials. Participants may also receive other drugs like bevacizumab or alectinib. The main goal is to provide ongoing a…

This study observes how abiraterone acetate tablets work in real-world settings for Chinese men with metastatic prostate cancer. Researchers will track safety, side effects, and effectiveness, including PSA levels and survival. The goal is to understand how well the drug performs…

This study tests different levels of a telephone-based weight loss program for cancer survivors who are overweight or obese. All participants start with a core program including written materials, a smartphone app, and optional coaching. Those who lose at least 2% of their weight…

This phase II trial tests a highly precise, short-course radiation therapy (SBRT) combined with hormone therapy for men whose PSA levels rise after prostate cancer surgery. The goal is to control the cancer while reducing side effects by delivering higher radiation doses in fewer…

This trial tests whether placing a dehydrated human amnion chorion membrane (dHACM) over the nerves during robot-assisted prostate removal helps men recover erectile function and urinary control sooner. The study enrolls men aged 40 to 80 with localized prostate cancer who have g…

This study tests a drug called sacituzumab govitecan (Trodelvy) in Japanese patients with advanced solid tumors, including certain breast and bladder cancers. The trial has two phases: first, to find the safest dose, and second, to see how well the drug shrinks tumors. Participan…

This study looks at whether a special program called Primary Care Connect (PC2) helps cancer survivors who also have conditions like high blood pressure, diabetes, or high cholesterol keep their heart risks under control during cancer treatment. About 266 adults with early-stage …

This phase 2 trial is testing whether giving the targeted drug olaparib (Lynparza) along with hormone therapy for 6 months before surgery can shrink or eliminate prostate cancer in men with high-risk disease and specific gene mutations. About 32 men will receive the treatment, th…

This study tests a drug called trastuzumab deruxtecan (T-DXd) in people with various advanced cancers that have a protein called HER2. The goal is to see if the drug can shrink tumors and control the disease. About 477 participants with cancers like bladder, cervical, ovarian, an…

This early-phase trial tests an experimental immunotherapy called ELI-002 7P in people with pancreatic or other solid tumors that have specific KRAS or NRAS gene mutations. The treatment aims to train the immune system to attack cancer cells. About 158 participants will receive t…

This study offers continued treatment with the cancer drug osimertinib to patients who have already benefited from it in a previous trial. The goal is to keep providing the drug while monitoring safety and side effects. About 37 adults with cancer who are still doing well on the …

This observational study follows about 1,600 men with metastatic hormone-sensitive prostate cancer who are taking darolutamide plus hormone therapy, with or without chemotherapy. Researchers will track how many men have undetectable PSA levels after one year, as well as overall s…

This phase 2 trial tests the drug bortezomib in 22 men with metastatic castration-resistant prostate cancer that has a specific genetic change (PTEN deletion). The main goal is to see if bortezomib can lower PSA levels by at least 30%. Participants receive bortezomib injections f…

This study tests a new drug called marlotamig (REGN7075) alone or with cemiplimab (Libtayo) and sometimes chemotherapy in people with advanced solid tumors. The goal is to find the safest dose and see if the combination can shrink tumors. About 933 participants are being recruite…

This study looks at how prostate cancer treatments, especially hormone therapy, affect heart health. It includes two parts: one that follows men over time to track heart problems, and another that tests whether a program of healthy eating, exercise, smoking cessation, and medicat…

This phase 3 trial tests whether adding the targeted drug abemaciclib to standard hormone therapy (abiraterone plus prednisone) can delay cancer growth in men with high-risk prostate cancer that has spread to bones or organs. Participants receive either abemaciclib or a placebo a…

This study tests a virus called AdAPT-001 that is injected directly into tumors to kill cancer cells. It is for adults with advanced solid tumors that have not responded to standard treatments. The trial will check if the virus is safe and whether it works better when combined wi…

This trial tests a minimally invasive treatment that uses microwaves to destroy only the cancerous part of the prostate, leaving healthy tissue intact. The goal is to control the cancer while avoiding common side effects of full prostate removal, such as urine leakage and erectil…

This early-phase trial tests a new drug, ASTX660, combined with the immunotherapy pembrolizumab in people with advanced solid tumors, including cervical and triple-negative breast cancers. The goal is to see if the combination is safe and can boost the immune system to fight canc…

This study is for men whose prostate cancer has returned in the same area after they already had radiation and surgery. The researchers want to see if giving a very precise, high-dose radiation treatment (called SBRT) along with the diabetes drug metformin can safely control the …

This study tests whether a device called Calypso, which tracks the prostate's position in real time during radiation, can reduce long-term side effects compared to standard image-guided radiation. 74 men with low- or intermediate-risk prostate cancer took part. The goal is to see…

This early-phase trial tests an experimental drug called IPH5301, which targets a protein called CD73 on cancer cells. The study involves 27 people with advanced solid tumors, including breast, lung, and pancreatic cancers. In the first part, IPH5301 is given alone to find a safe…

This phase 2 trial investigates whether adding a targeted radiation therapy called Lu-PSMA to the standard hormone drug enzalutamide can delay cancer progression in men with metastatic castration-resistant prostate cancer (mCRPC) who have not received chemotherapy. Participants r…

This study looks at whether a whole-food, plant-based diet can help overweight or obese men with prostate cancer who are on hormone therapy (ADT) control their weight and reduce inflammation. About 76 men will either receive free plant-based meals at home or standard nutrition ad…

This study tests a device called Vanquish that uses water vapor (steam) to destroy prostate cancer tissue in men with intermediate-risk, localized prostate cancer. The goal is to control the cancer while avoiding common side effects like incontinence and impotence. About 400 men …

This study tests whether using highly focused radiation (SBRT) on a limited number of growing cancer spots can help control the disease in patients with metastatic breast or genito-urinary cancers. Instead of switching to a new drug when some tumors start growing, doctors will ta…

This study tests four different tools—coaching, education, text messages, and health coaching—to help cancer survivors improve their diet, physical activity, and weight. About 350 adults who have completed treatment for several cancer types will use these tools for up to 48 weeks…

This early-phase study tests two drugs together—nivolumab (Opdivo) and Radium-223 (Xofigo)—in 39 men with metastatic castration-resistant prostate cancer that has spread to the bones. The main goals are to check safety and see if the combination can reduce tumor DNA in the blood.…

This early-phase trial is testing whether giving an extra dose of the immunotherapy drug Sipuleucel-T can strengthen the immune system's attack on prostate cancer that has spread and stopped responding to hormone therapy. Fifteen men with this advanced cancer will receive three i…

This phase 2 trial tests whether giving a radioactive drug (177Lu-PSMA) before precise radiation (SBRT) can better control prostate cancer that has come back in 1 to 5 spots. About 93 men with recurrent prostate cancer will receive either SBRT alone or the drug first, then SBRT. …

This study tests a newer, highly precise radiation technique for men with high-risk prostate cancer. The treatment delivers a strong dose to the pelvic lymph nodes while boosting radiation to the prostate itself. Researchers want to see if this approach controls the cancer better…

This study is testing whether adding an immunotherapy drug (ONC-392) to a targeted radiation therapy (Pluvicto) can help men with a hard-to-treat form of advanced prostate cancer. About 148 participants whose cancer has worsened despite standard treatments will receive either a l…

This Phase 3 trial compares two hormone therapies (GnRH antagonist vs GnRH agonist) given alongside radiation for men with very high-risk localized or locally advanced prostate cancer. The main goal is to see which combination better delays cancer progression. The study enrolled …

This early-stage trial tests a new drug called LY4101174 in people with advanced solid tumors, including bladder, breast, and lung cancers. The drug is an antibody-drug conjugate designed to target and kill cancer cells. The study will check if the drug is safe, tolerable, and ef…

This early-stage trial tests a new drug called EM-I-2024, made from a modified enterovirus, in 24 adults with advanced solid tumors that cannot be surgically removed and have not responded to other treatments. The drug is given either intravenously or directly into the artery fee…

This study aimed to see if giving the immunotherapy drug pembrolizumab before radical prostatectomy could reduce lymph node invasion in high-risk prostate cancer patients. Participants would have received three doses of the drug before surgery. However, the study was withdrawn be…

This study looks at using heat or cold to destroy small clusters of prostate cancer that have spread to other parts of the body. It is for men who cannot have standard radiation therapy. The goal is to control the cancer with a quick, low-risk procedure that allows a fast recover…

This early-phase study tests a combination of two drugs—guadecitabine and pembrolizumab—in about 60 people with advanced solid tumours (like lung cancer) that no longer respond to standard therapies. The main goal is to find the safest dose and check for side effects. Researchers…

This study tests a combination of two drugs, pembrolizumab and lenvatinib, in people with a rare and aggressive form of prostate cancer called neuroendocrine prostate cancer that has spread. The goal is to see if this treatment can slow or stop tumor growth. About 45 participants…

This early-phase trial tests two oral cancer drugs, niraparib and neratinib, given together. The first part aims to find the safest dose in people with advanced solid tumors. The second part checks if that dose can keep platinum-resistant ovarian cancer from growing for at least …

This phase 3 trial tests whether adding enzalutamide to standard hormone therapy and radiation can delay cancer spread in 802 men with high-risk localized prostate cancer. Participants receive either enzalutamide or a conventional anti-androgen alongside hormone therapy and radia…

This study looks at men whose prostate cancer has come back in a few spots (oligometastatic) and who have certain gene mutations. It compares standard care (hormone therapy plus radiation) against the same treatment plus a 6-month course of two drugs (niraparib and abiraterone wi…

This study tests whether adding darolutamide to standard hormone therapy and radiation can delay cancer spread in men with very high-risk localized prostate cancer. About 1,100 men are participating in this phase 3 trial. The goal is to see if the combination helps keep the cance…

This phase II trial tests whether using MRI to map the exact location of recurrent prostate cancer after prostatectomy allows doctors to safely deliver a higher radiation dose to the tumor while sparing healthy tissue. The study enrolled 37 men whose PSA levels rose after surgery…

This study tests a combination of a targeted drug (niraparib), hormone therapy, and precise radiation for men with high-risk or node-positive prostate cancer. The goal is to find the safest dose and see if this approach improves the chance of staying cancer-free for three years. …

This small study tests whether a 3D ultrasound system can help doctors place extra radioactive iodine seeds precisely into prostate tumors. Fifteen men with low- or intermediate-risk prostate cancer will receive the boost during standard brachytherapy. The main goal is to see if …

This phase 2 trial tests a combination of hormone therapy, external beam radiation, and MRI-guided internal radiation implants for men with unfavorable-intermediate to very high-risk prostate cancer. The goal is to see if this precise approach causes fewer urinary side effects th…

This study tests whether adding an experimental drug called NP137 to standard immunotherapy (PD-1/PD-L1 blockers) can help shrink or control advanced solid tumors that are stable or resistant to treatment alone. About 57 adults with various advanced cancers will receive the combi…

This Phase 2 trial is testing a drug called PRL3-zumab in 60 people with advanced solid tumors that have not responded to standard treatments. PRL3-zumab is an antibody designed to attach to a protein called PRL3 found on cancer cells, potentially helping the immune system attack…

This study tests an oral drug called selpercatinib in people with advanced solid tumors that have RET gene alterations, including certain lung, thyroid, and colon cancers. The goal is to find the best dose and see if the drug can shrink tumors. About 857 participants are enrolled…

This early-stage study tests a new radioactive drug called AB001 in 80 men with advanced prostate cancer that has stopped responding to hormone therapy. The drug delivers a powerful alpha radiation dose directly to cancer cells. The main goals are to check safety and find the bes…

This pilot study tests two ultra-high-dose radiation schedules in 31 men with intermediate-risk prostate cancer. One group gets five high-dose sessions over a week; the other gets a single massive dose. The goal is to see if these shorter treatments are safe and can control the c…

This phase II trial tests whether adding the immunotherapy drug durvalumab to precise radiation (SBRT) can better control prostate cancer that has returned and spread to a few spots (oligometastases). About 96 men with hormone-sensitive prostate cancer will be randomly assigned t…

This phase 3 trial is testing whether adding local ablative therapy (radiation or surgery) to all visible cancer sites, on top of standard hormone therapy, improves outcomes for men with hormone-sensitive prostate cancer that has spread to a few spots (oligometastatic). About 409…

This study tests whether giving a precise, high-dose radiation treatment (SBRT) before prostate removal surgery is safe and effective for men with high-risk prostate cancer. Sixteen men with aggressive prostate cancer (Gleason score 8 or higher or signs of spread) will receive ra…

This study tests whether a very short course of MRI-guided radiation (just 5 sessions) is safe and effective for men with low- or intermediate-risk prostate cancer. Traditional radiation can take 7-8 weeks, but this approach aims to cut that time dramatically. The trial involves …

This study follows 3000 men with prostate cancer to compare how proton therapy and standard photon radiation affect quality of life and side effects like bowel urgency. Participants receive standard care at proton or photon centers, and researchers track bowel, urinary, and sexua…

This Phase I trial tests a combination of two oral drugs, defactinib and VS-6766, in people with advanced solid tumors such as non-small cell lung cancer, low-grade serous ovarian cancer, and pancreatic cancer. The study aims to find the safest dose and evaluate how well the drug…

This study tests whether using MRI guidance to deliver an extra dose of radiation directly to the tumor can improve prostate cancer treatment. Forty men with localized prostate cancer will receive standard radiation to the whole prostate plus a targeted boost to the visible tumor…

This phase 2 study tests pembrolizumab (Keytruda) in 40 men with metastatic castration-resistant prostate cancer that has specific genetic flaws (mismatch repair deficiency or CDK12 inactivation). The goal is to see if the drug can shrink tumors or slow the cancer. Researchers wi…

This early-phase study tests whether a bicalutamide implant placed directly into the prostate can replace standard hormone shots for men with localized prostate cancer receiving radiation. About 20 participants with intermediate- or high-risk cancer will receive the implant plus …

This study tests whether giving an extra-high dose of radiation to the most aggressive parts of prostate tumors, guided by MRI, can better control cancer while reducing side effects. About 164 men with prostate cancer will receive either the standard radiation or the standard plu…

This study tests a new way for cancer doctors and primary care doctors to work together to help cancer survivors manage other health problems like high blood pressure, diabetes, and high cholesterol. About 800 adults with certain cancers and at least one of these conditions will …

This study tests a new way to deliver high-dose radiation (SABR) for low- and intermediate-risk prostate cancer. The technique, called SUPR-SABR, is designed to avoid the urethra, rectum, and pudendal artery to reduce urinary and bowel side effects. About 42 men will receive five…

This early-phase trial tests an experimental drug called IMP321, which activates immune cells, in combination with other cancer treatments like chemotherapy or immunotherapy. The study includes 83 people with advanced solid tumors, including lung and bladder cancers. The main goa…

This phase 2 trial tests enfortumab vedotin, a drug that targets cancer cells, alone or with other drugs in 34 men with metastatic castration-resistant prostate cancer that has spread and stopped responding to hormone therapy. The goal is to see if the drug can shrink tumors, low…

This early-stage trial is testing a new cell therapy called GK01 combined with a PD-1 immune checkpoint inhibitor in 15 people with advanced solid tumors (such as lung, stomach, or colorectal cancer). The main goal is to see if the combination is safe and tolerable, while also ch…

This study tests whether giving a combination of two hormone therapies (leuprorelin and darolutamide) for 24 weeks before prostate removal surgery can reduce or eliminate cancer more effectively than either drug alone. It involves 144 men with intermediate to high-risk prostate c…

This phase III trial tests whether adding rucaparib to standard enzalutamide therapy helps men with metastatic castration-resistant prostate cancer live longer or delay cancer growth. The study involves 61 participants and compares the combination against enzalutamide alone. Rese…

This study looks at whether men with a certain type of advanced prostate cancer (castration-resistant) who have inherited DNA repair gene mutations respond better to the chemotherapy drug carboplatin. Researchers will first screen participants for these genetic changes, then trea…

This study compares two radiation methods for men with low- or intermediate-risk prostate cancer: low dose rate (permanent seed implants) and high dose rate (temporary radioactive needles). The main goal is to see which approach better preserves urinary quality of life. About 140…

This trial compares two types of brachytherapy boost (HDR vs LDR) given alongside external beam radiation for intermediate- and high-risk prostate cancer. The goal is to see which one provides better cancer control and quality of life with fewer side effects. About 195 men are ta…

This study compares a standardized active surveillance protocol to usual care for men with low-risk prostate cancer. The goal is to see if a clear set of rules for when to start treatment can reduce unnecessary treatments and side effects without raising the risk of cancer spread…

This study tests a new drug called TYRA300 in people with advanced bladder cancer or other solid tumors that have a specific change in the FGFR3 gene. The goal is to find the best dose and see if the drug can shrink tumors. About 310 adults whose cancer has not responded to stand…

This study looks at whether removing the prostate and nearby lymph nodes, in addition to standard drug therapy, helps men with prostate cancer that has spread to a few bones live longer and delay the cancer becoming resistant to treatment. About 452 men with intermediate- or high…

This study tests an oral drug called selpercatinib (LOXO-292) in children with advanced solid or brain tumors that have a specific RET gene change. The trial has two parts: first finding a safe dose, then measuring how many children's tumors shrink. About 36 children whose cancer…

This study is for men whose prostate cancer has returned after surgery, shown by a rising PSA. It compares standard hormone therapy plus radiation to a stronger version that adds enzalutamide. The goal is to see if the enhanced treatment keeps the cancer from progressing longer. …

This trial is testing a new way to treat prostate cancer that returns after the prostate has been removed. It combines a very short course of highly targeted radiation (just 5 sessions) with 6 months of hormone therapy. The goal is to see if this approach can control the cancer w…

This study tests an experimental drug called [Ac-225]-PSMA-62 in people with prostate cancer that has spread to other parts of the body. The drug delivers a small amount of radiation directly to cancer cells. The main goals are to find the safest dose and to see if it can shrink …

This phase 3 study tests whether combining two drugs—cabozantinib (a targeted therapy) and atezolizumab (an immunotherapy)—works better than standard hormone therapy for men with metastatic castration-resistant prostate cancer that has progressed after one prior hormone treatment…

This study tests whether a daily high-dose omega-3 supplement (fish oil) can slow the rise of PSA levels in men whose prostate cancer has returned after initial treatment. About 40 men with a rising PSA but no spread will take either the supplement or a placebo for one year. The …

This pilot study is testing whether robot-assisted prostate removal for localized prostate cancer can be safely performed as outpatient surgery, meaning patients go home the same day. Twenty men will be enrolled and followed for one month to see if they can avoid a conventional h…

This study looks at whether adding a high-precision type of radiation called SBRT to usual cancer treatments (like hormone therapy or chemo) can delay cancer growth in people with breast, lung, or prostate cancer that has spread to 1 to 5 bones. About 168 adults aged 18-75 with g…

This phase 2 trial tests whether taking omega-3 (EPA) supplements can reduce inflammation and slow cancer cell growth in men with high-risk prostate cancer who choose surgery. 130 participants will take either EPA capsules or a placebo for 14 months, starting before surgery. Rese…

This study tested whether a shorter, more intense radiation schedule (5 sessions) works as well as the standard longer schedule (26 sessions) for men with prostate cancer. The goal was to see if the shorter treatment could control the cancer just as well, based on PSA levels afte…

Surgeons removing a prostate for cancer can struggle to tell cancerous tissue from healthy tissue, and cancer left at the edge of the removed gland is usually found only days later under a microscope. This pilot study at Geneva University Hospitals tests whether a PET/CT scanner …

Researchers at Herlev Hospital are studying whether multiparametric MRI can help doctors decide which men with low-risk prostate cancer can safely stay on active surveillance instead of getting treatment. The trial enrolls 150 men with newly diagnosed low-risk prostate cancer who…

This study is testing whether a special type of MRI (multiparametric MRI) can better identify which men with low-risk prostate cancer can safely delay treatment. About 200 men already on active surveillance will receive the MRI, and if suspicious areas are found, they will get ad…

This study aims to develop an artificial intelligence (AI) model that combines two advanced imaging techniques—multiparametric MRI and PSMA PET/CT—to more accurately diagnose prostate cancer. By analyzing data from up to 1,500 patients, the AI model is designed to identify clinic…

This study looks at whether a special type of MRI, called multiparametric MRI, can more accurately determine the stage of prostate cancer in people who are newly diagnosed and planning surgery. The goal is to see if this imaging method helps doctors find aggressive cancers and ma…

Researchers are running a registry to see how a PET scan using PYLARIFY (piflufolastat F18) affects real-world care for men with prostate cancer. The study will follow 500 men for up to 5 years, collecting data every 6 months on their diagnosis, treatment, and outcomes. The goal …

This study is testing whether a special MRI contrast called hyperpolarized pyruvate can help doctors see prostate tumors more clearly than standard MRI. About 130 men with prostate cancer will receive the contrast before imaging. The goal is to improve cancer detection and diagno…

Researchers are studying whether a blood test can detect prostate cancer by finding prostasomes, tiny particles that prostate cancer cells release into the blood. The trial enrolls men with elevated PSA levels or diagnosed prostate cancer who have not yet received treatment. The …

This expanded access program lets people with advanced solid tumors receive an investigational imaging agent called MNPR-101-DFO*-89Zr before a PET/CT scan. The agent is designed to bind to uPAR, a protein found at higher levels in some tumors than in normal tissue. The goal is t…

This study compares a new radioactive tracer called 18F-DCFPyL with standard tracers to see if it can better detect where prostate cancer has spread in the body. About 96 men with metastatic prostate cancer will receive both tracers and undergo PET/CT scans. The goal is to measur…

This phase 2 trial tests whether a radioactive tracer called 18F-DCFPyL can improve PET/CT scans for men with high-risk or recurrent prostate cancer. About 360 men will receive the tracer and undergo imaging to see if it more accurately finds cancer outside the prostate or after …

Researchers at Northwestern University are testing an artificial intelligence tool that reads prostate MRI scans to find suspicious lesions. The goal is to see whether this AI can detect clinically significant prostate cancer as well as or better than the standard PIRADS scoring …

This study tests a new imaging agent called 68Ga-FAPI-46, which targets a protein (FAP) found around tumor cells. Researchers want to see where this tracer goes in the body and whether it can highlight prostate cancer on PET scans. About 30 people with prostate cancer who are alr…

This study compares two methods for detecting serious prostate cancer: MRI fusion biopsy and micro-ultrasound (ExactVu). Researchers want to see if micro-ultrasound can find dangerous cancers as well as MRI, and if it can be used in communities with limited healthcare access. The…

This trial tests whether artificial intelligence can detect anxiety and depression in cancer patients by analyzing their facial expressions and subtle skin color changes from video. The AI uses computer vision to estimate heart rate and read emotional cues, aiming to flag patient…

This trial tests whether an experimental imaging agent, 18F-LNC1007, can improve the detection, staging, and recurrence monitoring of tumors compared to the standard 18F-FDG PET/CT scan. Adults with suspected or confirmed tumors will receive both types of scans within a week, and…

This study is testing a new blood test that looks at RNA from tiny particles called exosomes to diagnose prostate cancer. Researchers will enroll 1,600 men with elevated PSA levels or other signs of prostate cancer. The goal is to see if this test can accurately detect cancer and…

This study tests a new device that measures blood counts from a tiny finger-prick sample in cancer patients. Researchers will compare these results to standard lab tests from regular blood draws. The goal is to see if the device is accurate enough to eventually allow patients to …

This study is testing whether a new blood test called ClarityDX Prostate can better identify men who have clinically significant prostate cancer. The test is given to men aged 40-75 with elevated PSA levels (3 ng/mL or higher) who are already scheduled for a prostate biopsy. Rese…

This study compares two imaging methods—multiparametric ultrasound (mpUS) and multiparametric MRI (mpMRI)—to see which better detects clinically significant prostate cancer in men scheduled for their first biopsy. Participants receive both scans before biopsy, and if either shows…

This study tests whether combining a special MRI analysis (called Habitat Risk Score) with blood and urine tests can more accurately rule out aggressive prostate cancer than the standard MRI reading. About 289 men with elevated PSA or abnormal exams will be enrolled. The goal is …

This study tests whether a special PET/CT scan (68Ga-PSMA-11) can help doctors plan more precise radiation for men whose prostate cancer has come back after surgery. About 193 men with a rising PSA level will be randomly assigned to have their radiation plan based on either the n…

This phase 3 study tests a new type of PET scan (64Cu-SAR-bisPSMA) to see if it can better detect prostate cancer that has come back after initial treatment. The study involves 220 adults with a rising PSA level after surgery or radiation. The goal is to improve detection so doct…

This study aims to create a screening tool that uses common blood test results to detect various cancers early. Researchers will analyze data from 10 million cancer patients and healthy individuals, using machine learning to find patterns. The goal is a low-cost, non-invasive tes…

This study tests whether a simple 30-second ECG using a handheld device can find undiagnosed atrial fibrillation (an irregular heartbeat) in people aged 65 and older with cancer. About 500 participants will be randomly assigned to either get the quick screening or usual care. The…

This pilot study is testing a new screening pathway for prostate cancer in men aged 55-65. Instead of relying only on PSA blood tests, participants with elevated PSA will also get a risk assessment and an MRI. The goal is to better distinguish between slow-growing cancers that do…

This study looks at whether combining PSMA-PET/CT and MRI scans can more accurately determine the extent of prostate cancer in men with intermediate- or high-risk disease. Researchers will compare scan results with tissue samples from 600 men who had their prostate removed. The g…

This study tests whether adding a PSMA PET scan helps doctors better diagnose significant prostate cancer in men whose MRI results are unclear or negative. About 660 men with no prior prostate cancer or biopsy will be randomly assigned to receive either standard care or an additi…

This study tests a special PET scan (18F-DCFPyL) to see if it can find prostate cancer spread that standard scans miss. Fifty men with castration-resistant prostate cancer starting enzalutamide will get the new scan. The goal is to better detect and monitor metastases, which coul…

This early study tests a new radioactive tracer called [68Ga]DOTA-IR-780-C-4 for PET/CT imaging in men with PSMA-positive prostate cancer. The goal is to see if it can accurately detect primary and metastatic lesions. Only 5 participants are enrolled, and they will receive the tr…

Researchers are studying whether a lower 3mg dose of pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) can prevent febrile neutropenia, a serious drop in infection-fighting white blood cells, in cancer patients after chemotherapy. The standard 6mg do…

This study tests whether empagliflozin, a drug used for diabetes, can prevent heart damage in cancer patients receiving strong chemotherapy (anthracyclines). About 220 adults with cancer but no prior heart failure will take either the drug or a placebo daily for 12 months. The go…

This study is testing a culturally adapted mindfulness program for Latino cancer patients and their family caregivers. The goal is to see if the program is practical and helpful for reducing stress and anxiety. About 68 patient-caregiver pairs will take part, with some starting t…

This study tests a supportive care program designed specifically for Black patients with advanced cancer. Participants will join weekly online sessions for four weeks, either practicing meditation or learning coping skills. The goal is to see if this culturally adapted program is…

This trial tests whether a program designed to boost social connections can improve the social and emotional well-being of young adults who had cancer. Participants, aged 22-39 and diagnosed between 15-39, will receive a video and planning tools to encourage more in-person intera…

This study tests a group counseling program called Healing HEARTS to help people with conditions like obesity, skin disease, cancer, HIV, diabetes, or chronic pain deal with internalized stigma. Participants will either join the counseling program or a peer support group. The goa…

This study tests a procedure called cordotomy, where a needle is guided into the spinal cord to block pain signals. It's for people with advanced cancer who have severe pain on one side of the body below the shoulder. The goal is to see if it reduces pain better than a fake proce…

This study trains home-care nurses to deliver a short, meaning-centered psychotherapy to cancer patients who are homebound. The goal is to see if this approach can reduce psychological distress and improve quality of life. The trial involves 81 participants and focuses on trainin…

This trial tests a biodegradable gel called SpaceOAR Vue that is injected between the prostate and rectum before radiation therapy. The gel temporarily pushes the rectum away to reduce radiation damage. About 500 men with intermediate-risk prostate cancer will be randomly assigne…

This study tests whether giving haloperidol alone or with chlorpromazine can safely calm severe agitation and confusion (delirium) in 70 advanced cancer patients in a palliative care unit. The main goal is to see if the drugs improve sedation scores within 24 hours. It is a phase…

This study compares two types of radiation therapy for low- or intermediate-risk prostate cancer: proton therapy (PBT) and intensity-modulated radiation therapy (IMRT). Both are thought to be equally effective at treating the cancer, but it's unclear which causes fewer side effec…

Researchers are testing a virtual stress-management program for people who care for a spouse or partner with a solid tumor cancer while also holding a job. The program teaches skills such as paced respiration, relaxation, and coping with work and caregiving demands across eight s…

This study looks at how cancer patients feel about using marijuana products (THC or CBD) compared to opioids for pain relief. Researchers will survey 200 adults with cancer-related pain who are already taking strong opioids. The goal is to understand patient preferences and perce…

Depression is common among cancer survivors, but many don't get help. This pilot study tests a text-based referral platform that sends tailored messages and a video to encourage survivors to take up a mental health referral. The study will enroll 60 cancer survivors with depressi…

Researchers are testing a five-session program called PRISM-SN for people aged 12 to 25 who were recently diagnosed with cancer and are receiving chemotherapy or radiation. The program teaches skills for managing stress, setting goals, reframing negative thoughts, finding meaning…

This study tests a type of talk therapy called dignity therapy, adapted for sexual and gender minority (LGBTQ+) cancer patients. A trained researcher will interview participants about their lives and create a poem or legacy document they can share with loved ones. The goal is to …

This study tests a program called CostCOM that helps cancer patients with the high costs of treatment. Many patients skip or delay care because of money worries. The program provides financial advice and connects patients to resources. Researchers want to see if it helps patients…

This pilot study explores how four different meditation practices—breathing only, focused attention only, mindfulness only, and a combination of all three—affect relaxation in cancer survivors. Many cancer patients experience stress and anxiety, and meditation may help reduce dis…

This study looks at whether combining exercise, supportive counseling, and a stimulant drug (methylphenidate) can help reduce severe fatigue in prostate cancer patients who are receiving radiation and hormone therapy. About 175 adults with prostate cancer and daily fatigue will b…

This study tests a program called ASCENT that helps cancer survivors manage pain using an educational guide and coaching from community health workers and pain care managers. The goal is to improve pain control and lower the risk of opioid misuse. About 660 adults with cancer-rel…

This study tests whether inhaling lavender aromatherapy oil can reduce anxiety and pain for cancer patients undergoing a bone marrow biopsy. About 45 adults with cancer will be asked to use the oil during the procedure. The goal is to see if this simple, drug-free approach is som…

This study tests a communication coaching program for adolescent and young adult cancer survivors (ages 18-35) who have finished treatment at least a year ago. Participants complete online sessions and AI coaching to improve how they talk with peers. The goal is to see if the pro…

This early-stage study tests a high-precision radiation treatment called stereotactic body radiation therapy (SBRT) for men whose prostate cancer has returned after surgery. The main goal is to find the safest dose by monitoring side effects in 26 participants. The treatment deli…

This trial tests a proactive care model for men with metastatic hormone-sensitive prostate cancer who are taking the drug apalutamide. The model focuses on four areas: education, prevention, management, and follow-up, to help patients understand their treatment, reduce side effec…

This trial tests whether six weeks of upper cervical chiropractic care can help adults who have finished cancer treatment but still struggle with chronic fatigue. The study focuses on whether such a trial is practical, looking at recruitment, adherence, and acceptability. Partici…

This study tests a program called TIPPI-R that teaches children with cancer and their families ways to manage pain and distress during treatment. About 100 children aged 0-18 will either receive the program or standard care. Researchers will compare how well they cope with pain a…

This study tests a new way to deliver radiation for prostate cancer that hasn't spread. By using real-time motion tracking during treatment, doctors hope to target the tumor more precisely and reduce common side effects like urinary and bowel problems. About 80 men with early-sta…

This study tests a telemedicine program called FOCUS that helps advanced cancer patients manage common symptoms like trouble sleeping, worry, tiredness, and low mood. The program uses counseling techniques delivered through a phone app. Researchers will enroll 120 adults with adv…

This study tests whether an internet-based pain coping skills program can help cancer survivors manage ongoing pain. About 456 adults who have completed cancer treatment or are on maintenance therapy will take part. Participants will either get the online program plus enhanced us…

This trial tests whether a virtual reality (VR) educational video can reduce anxiety and improve satisfaction in adults starting their first course of external beam radiotherapy for cancer. Half of the 122 participants will watch a VR video through a headset before treatment, whi…

This study tests an online pathway called iPath*D that guides cancer patients who report depression symptoms from screening to treatment options. The goal is to see if the tool is acceptable and easy to use for adults starting cancer treatment. Researchers will measure usability,…

This study tests the DISCO app, designed to help cancer patients talk with their doctors about treatment costs. About 254 adults newly diagnosed with breast, prostate, lung, or colorectal cancer will use the app to become more confident in asking cost-related questions. The goal …

This study tests a digital program called EMBody for cancer survivors aged 16-25 who finished treatment up to seven years ago. The program uses short films and reflection activities to help them develop a healthier mindset about their body. Researchers want to see if it improves …

This trial tests a mindfulness program that blends stress-reduction techniques with Christian principles to improve well-being in Black adult cancer survivors. Participants take part in a silent mindfulness retreat, focus groups, interviews, and questionnaires. The study measures…

This study tests whether a smartphone app that teaches mindfulness can help reduce stress in people who have finished cancer treatment. About 345 cancer survivors will be randomly assigned to use the app right away or wait three months. The goal is to see if the app makes a real …

This trial tests whether an AI-powered chatbot can help reduce anxiety and improve coping in men about to have prostate cancer surgery. Participants will either receive standard preoperative communication or also have access to a large language model (LLM) that answers their ques…

This study is testing whether a daily testosterone gel can reduce fatigue and improve sexual function in men aged 55 and older who have cancer and low testosterone. The trial involves 230 participants who will apply either the gel or a placebo for six months. Researchers will mea…

This study tests whether adding an extra numbing injection inside the prostate can reduce pain during a prostate biopsy. Fifty men undergoing the procedure will receive either standard numbing of the skin or the standard plus the extra injection. Pain levels are measured before, …

This phase 2 trial tests whether a daily dose of EGCG, a compound found in green tea, can reduce frailty and inflammation in people aged 65 and older who have survived cancer. About 118 participants will take either EGCG or a placebo for 12 weeks. The study is currently suspended…

This study tests whether a financial navigation and counseling program (CostCOM) can help newly diagnosed cancer patients who are struggling with costs or basic needs like food and housing. About 91 patients will either get the program, educational materials, or usual care. The g…

This study tests a 7-session, peer-led self-management program for 234 cancer survivors who recently finished treatment with curative intent. The program aims to reduce anxiety and depression by teaching symptom management skills in a group setting. Participants are from central …

This study is testing a 5-session telehealth program called CASA that helps advanced cancer patients and their caregivers cope with emotional and spiritual challenges. The program is designed for people with stage III or IV cancer and their caregivers. The goal is to see if it im…

This study tests whether a structured home-based exercise program combining strength and aerobic training can improve quality of life, fitness, and immune function in 150 men with prostate cancer. Participants are randomly assigned to either the exercise program or usual care. Th…

This study compares two ways of giving nutrition advice to cancer patients who have lost weight: video calls from home versus in-person hospital visits. Eighty adults with cancer and weight loss will receive personalized dietary counseling every two weeks for 12 weeks. The goal i…

This phase 2 trial is testing whether a special type of radiation therapy (SAbR) that avoids the nerves involved in erections can help preserve sexual function in men with localized prostate cancer. About 124 men will be randomly assigned to receive standard SAbR or a version tha…

This study compares listening to Holy Qur'an recitation versus calming music before bed in children aged 6 to 10 who are undergoing chemotherapy. Sleep problems are common in these children, and the goal is to find a safe, non-medication way to improve sleep quality. Ninety child…

This study tests a new radiation technique for men whose prostate cancer returns after surgery. Instead of many standard treatments, this approach uses daily scans to adjust the radiation beam precisely, potentially reducing side effects and shortening the number of sessions. Abo…

This study tests whether up to two doses of psilocybin (the active ingredient in magic mushrooms) can safely reduce depression in adults who have both cancer and major depressive disorder. About 56 participants will receive either psilocybin or a placebo in a first session, and t…

This study tests whether a brief behavioral therapy (BBT-CI) or a healthy eating education program (HEAL) works better for reducing insomnia in cancer patients. About 400 adults with stage I-IV cancer who are currently receiving treatment and have sleep problems will take part. T…

This study looks at whether giving a numbing injection (called a TAP block) early or late during robotic prostate surgery helps reduce pain afterward. About 94 men with prostate cancer will take part. The goal is to find the best timing to lower pain scores and the need for stron…

This study tests whether a mobile app called SUPPORT+ can improve quality of life for adults with advanced cancer who are no longer receiving anticancer treatment. Participants use the app to report symptoms weekly, get self-care tips, and receive nurse follow-up if symptoms are …

This study tests a personalized rehabilitation program designed to help men recover their sexual quality of life after prostate removal for cancer. About 135 men will take part, with half receiving the program and half receiving standard care. The goal is to see if the program im…

This pilot study explores whether chiropractic adjustments to the upper neck can reduce chronic fatigue in adults who have finished cancer treatment. About 40 cancer survivors who are currently cancer-free will receive either immediate or delayed chiropractic care for 6 to 12 wee…

This study gives 250 advanced cancer patients $1,000 each month for a year to see if it reduces financial stress and improves quality of life. Participants also complete surveys every three months. The goal is to learn whether extra income can help patients stick to treatments an…

This study aimed to see if a 12-week supervised exercise program could improve quality of life and physical fitness in men with advanced prostate cancer receiving hormone therapy. Participants would have been randomly assigned to either the supervised program or usual care with e…

This study tests whether a special cooling mat can reduce hot flashes and night sweats in people taking hormone therapy for breast or prostate cancer. About 40 participants will use the mat for 8 weeks and track their symptoms. The goal is to see if this simple, non-drug approach…

This study planned to compare two types of pelvic floor rehabilitation for men who still have urinary incontinence more than a year after prostate removal. One method uses standard Kegel exercises, while the other focuses on whole-body postural control. The goal was to see which …

This study tests whether cancer patients who visit the emergency room for urgent problems benefit from being immediately referred to a palliative care team. The goal is to see if this reduces aggressive treatments and hospitalizations in the last month of life. The trial involves…

This study tests whether eating only within a 10-hour window each day can help prevent frailty in people over 55 who are on hormone therapy for prostate cancer. Frailty makes it harder to recover from stress and can lead to loss of independence. The trial will enroll 30 participa…

This study tests whether electroacupuncture (a type of acupuncture with mild electrical pulses) can help cancer patients and survivors with clusters of symptoms like memory problems, fatigue, insomnia, anxiety, and depression. Seventy participants will receive either real electro…

This study tests whether a mobile health program can help adolescents and young adults (ages 15-39) who finished cancer treatment become more physically active. Participants get a personalized activity plan, a fitness tracker, access to an online survivor community, and motivatio…

This study tests whether a phone app called OnKO-Tips&Tricks can improve the quality of life for adolescents and young adults (ages 15-25) recently diagnosed with cancer. The app helps with daily check-ins, education, and connecting with a nurse coordinator. Researchers will comp…

This study tests whether nature-based therapies can reduce fatigue and improve sleep, mood, and concentration in cancer survivors. 172 participants will be assigned to real forest bathing, a virtual reality forest experience, guided imagery, or a waitlist. Each session lasts 30 m…

This study tests whether an extra meeting with a team of doctors, a palliative care specialist, and a psychologist can help patients with advanced cancer feel less torn about their next treatment. 62 adults with metastatic lung, breast, colon, ovarian, or prostate cancer who need…

This trial tests a new surgical method called NeuroSAFE, which uses real-time tissue analysis during robotic prostate removal to help surgeons avoid damaging nerves that control erections and bladder function. About 407 men with prostate cancer will be randomly assigned to receiv…

This study looks at whether men with intermediate-risk prostate cancer can follow a Mediterranean diet before their surgery to remove the prostate. The goal is to see if this diet is practical and well-tolerated. Twelve participants will eat specially prepared meals and then unde…

This pilot study aims to see if a brief educational session can increase the number of Black men with aggressive prostate cancer who complete genetic testing. Researchers will enroll 50 men who identify as Black or multiracial and have high-risk prostate cancer. Participants will…

Researchers are studying whether a mobile health app called myAria helps adult prostate cancer patients track symptoms, share health data, and feel more empowered during treatment. Participants use the app to log side effects and well-being, complete questionnaires, and view a no…

This study reviews medical records of 72 American Indian patients treated with immunotherapy for cancers like lung cancer, melanoma, and kidney cancer. Researchers compare their outcomes—such as how long the cancer is controlled and side effects—to those of White patients. The go…

This study follows over 64,000 adults who grew up on farms to see if early exposure to pesticides and other agricultural factors is linked to cancer. Participants fill out an online questionnaire and may provide biological samples. Researchers will track their health over many ye…

This study aims to understand what helps or hinders a positive experience for Asian patients being treated for cancer at MD Anderson. Researchers will survey former patients and healthcare providers to identify key factors. The goal is to use these insights to improve care and su…

Older adults with cancer who need intensive care often face a higher risk of dying, and delays in moving them from the emergency department to the ICU may add to that risk. This study reviews the medical records of 150 patients aged 65 and older with solid or blood cancers who we…

This study looks back at the records of 625 men who had robotic prostate surgery for localized prostate cancer. It compares a newer single-port method with the standard multi-port approach to see which leads to fewer complications and better urinary control. The goal is to gather…

This study watches how men with a certain advanced prostate cancer (mCRPC) do when taking the drugs olaparib and abiraterone in everyday medical practice. It will track about 250 patients for up to 2 years to see how long they stay on treatment and what happens next. The goal is …

This study follows nearly 90,000 farmers, their spouses, and pest control workers in Iowa and North Carolina over many years. Researchers track their exposure to pesticides and other farm chemicals, then monitor who develops cancer or other diseases. The goal is to identify which…

This study enrolls up to 10,000 cancer patients at the National Cancer Institute who are not on an active treatment research protocol. Participants receive standard medical care, including lab tests and scans, while researchers collect their health information to build a data rep…

This study is testing whether regular screening for prostate, lung, colorectal, and ovarian cancers can reduce deaths from these diseases. About 154,900 men and women aged 55-74 were randomly assigned to either get screened or receive usual care. Researchers are tracking cancer c…

This study collects blood, bone marrow, urine, and tissue samples from up to 6,000 people with solid tumors, blood cancers, or non-cancerous blood disorders, as well as from their healthy family members who are stem cell donors. The samples are stored and used in research to bett…

This study looks at whether combining a genetic test called the Genomic Prostate Score (GPS) with MRI scans can help doctors better choose men with prostate cancer for focal therapy, which treats only the cancerous part of the prostate. Researchers will analyze data and tissue sa…

This study aimed to evaluate how community cancer centers test for biomarkers in common solid cancers like breast, lung, and colorectal cancer. Researchers planned to survey pathology practices to see if they follow guidelines for key tests and how quickly results are reported. T…

Researchers are examining whether the Gleason score, prostate-specific antigen (PSA) level, and clinical stage can predict treatment failure, death, and quality of life in men who received radiation therapy for localized prostate cancer. The study reviews medical records and ques…

This study tests a web-based education tool called HOPE-Genomics that teaches cancer patients about their genetic test results. About 465 adults with breast, colorectal, lung, ovarian, pancreatic, or prostate cancer are taking part. The goal is to see if the tool helps patients r…

This study follows 2,500 prostate cancer survivors who had surgery at City of Hope. Researchers track their quality of life, side effects, and long-term health for years after treatment. The goal is to learn what survivors experience over time and find ways to improve their care.

This study tests whether a special PET scan, done before prostate removal surgery, can predict if prostate cancer will come back. About 175 men with high-risk prostate cancer will get the scan, then have surgery, and be followed for up to 5 years. The goal is to see if this scan …

This study is testing whether a special type of MRI scan can show early signs that high-risk prostate cancer is responding to treatment. About 32 men will get the scan before and during therapy, and results will be compared to standard tissue exams after surgery. The goal is to f…

This study enrolls 400 adolescents and young adults (ages 18-39) recently diagnosed with various cancers. Participants are randomly assigned to either choose which health-related questions they answer or receive a fixed set of questions. The goal is to see if giving patients a ch…

This study is testing a 24-week program that combines nutrition counseling, exercise, sleep tips, and stress management for cancer survivors who are overweight. Researchers want to see if the program is practical and helpful for improving sleep quality, reducing stress, and boost…

This study will collect blood and tumor tissue from up to 50,000 adults with hereditary or genetic-linked cancers. Researchers will use these samples to create lab-grown tumor models, like mini-tumors, to study how these cancers work and test new treatments. The goal is to better…

Researchers are testing an online decision support tool called Gene PilotLX to see if it helps Latinx cancer patients make informed choices about tumor genomic testing. Tumor genomic testing looks for genetic changes in a tumor that might guide treatment or reveal hereditary risk…

This study reviews medical records from 232 adults with cancer who received the immunotherapy drug M7824. The goal is to create a complete list of side effects caused by the drug. By understanding these risks, doctors hope to prevent or reduce them in future cancer treatments.

This study looks back at the medical records of 500 children and adults with cancer who received immunotherapy at the National Cancer Institute. The goal is to understand the side effects, like inflammation and immune reactions, that can happen with these treatments. By learning …

This study compares two imaging methods—micro-ultrasound and MRI—for monitoring prostate cancer in men on active surveillance. Researchers will perform biopsies guided by each technique to see which better detects cancer progression. The goal is to determine if micro-ultrasound c…

This registry study is collecting blood samples and health data from 1,000 people being evaluated for prostate cancer. The goal is to test the accuracy of a new blood-based test called PROSTest, which looks for genetic signals of prostate cancer activity. Researchers hope this te…

This study looks at whether giving men with low-risk prostate cancer two extra tests—a genomic test (GPS) and a special MRI—helps them stick with active surveillance (monitoring instead of immediate treatment). Researchers will track 222 men for 18 months to see if these tests im…

This study aims to collect and analyze genetic and clinical information from up to one million people with prostate, bladder, or kidney cancer. The goal is to better understand tumor biology and how this information can be used to improve treatment decisions and outcomes. Partici…

This study looks for genetic changes that raise the risk of prostate cancer, especially in men diagnosed young or with a family history. Over 23,800 men with prostate cancer provided DNA samples. The goal is to find inherited genes linked to the disease, which could improve risk …

This study is collecting stool and blood samples from 120 advanced cancer patients receiving immunotherapy combinations. Researchers want to see if the types of bacteria in the gut and certain immune markers can predict which patients will develop serious side effects. The goal i…

This study looks back at medical records of children and young adults with solid tumors or lymphoma who also have a tumor thrombus—a blood clot that forms in a vein due to tumor pressure or invasion. Researchers will gather data on who received blood thinners or procedures like s…

This study looks at how cancer patients use complementary and alternative medicine (CAM), such as herbal products and aromatherapy. Researchers will survey 500 patients and hold focus groups with 30-60 survivors to understand their needs, information sources, and any potential sa…

This study is testing whether a chatbot can help parents of children with cancer learn about genetic risks and decide whether to get tested themselves. The chatbot provides education and support as an alternative to speaking with a genetic counselor. The goal is to make it easier…

This study is testing whether a new device called Liberty can accurately measure blood counts from a finger-prick sample compared to standard venous blood draws. Researchers will collect paired capillary and venous blood samples from healthy volunteers and cancer patients receivi…

This study looks at how community cancer clinics screen for health-related social needs, like help with housing, food, or transportation. Researchers will work with 144 clinic staff to understand what helps or hinders screening. The goal is to create custom plans to make screenin…

This study tests whether low-intensity electrical stimulation of nerves near the prostate can help surgeons monitor and preserve erectile function during robot-assisted prostate removal. Twenty men with localized prostate cancer and normal erectile function will receive the stimu…

This study looks at inherited gene changes (like BRCA) in men with prostate cancer to understand how common they are and how they affect treatment. Researchers will collect saliva samples and health information from 1,360 men in Washington state. The goal is to improve cancer car…

This study follows 900 cancer survivors from six small island nations (Antigua, Dominica, Grenada, Saint Kitts, Saint Lucia, and Saint Vincent) to understand how traveling overseas for cancer treatment affects their health and social support. Researchers will compare those who se…

This study explores whether a genetic test can identify prostate cancer patients at higher risk for urinary side effects from radiation therapy. Researchers will track side effects in 208 men with early-stage prostate cancer who receive stereotactic radiation. The goal is to see …

This study looks at whether cancer survivors can use a smartwatch and a phone app to regularly report their symptoms and activity levels. Fifty adults who have finished cancer treatment and have stable disease will wear a smartwatch for about four months and fill out weekly quest…

This study tests a training program called CASCADE for family caregivers of people with advanced cancer. The goal is to see which parts of the training best help caregivers support patients in making medical decisions. 256 caregivers are taking part in different combinations of c…

This study tests whether giving cancer patients a drug vigilance card helps them avoid medication errors and interactions when seeing other doctors. One hundred patients on oral chemotherapy or targeted therapies at Limoges University Hospital will use the card. Researchers will …

This study is not testing a new treatment. Instead, it observes how 400 men with advanced prostate cancer are actually treated in Russia, and looks for biomarkers in their tumor samples. The goal is to understand current practices and identify factors that might influence outcome…

This study is developing an artificial intelligence model to predict which patients with advanced prostate cancer are at higher risk of developing a more severe form called castration-resistant prostate cancer. The AI will analyze MRI images, biopsy slides, and clinical data from…

This study was designed to see how accurately patients report their own medication and healthcare use in diaries compared to official health insurance records. It planned to include people with diabetes, arthritis, kidney disease, or prostate cancer. However, the study was withdr…

This study follows 214 men treated for prostate cancer to see how many develop lower limb lymphedema (leg swelling) and who is most at risk. Participants attend check-ups every three months for 18 months. The goal is to better understand this side effect and its impact on quality…

This study looks at how genetic differences (SNPs) in prostate cancer patients affect their response and side effects to the drug abiraterone. Researchers will analyze DNA from 600 patients taking abiraterone plus prednisone and bicalutamide. The goal is to find genetic markers t…

This phase 2 trial is testing how the immunotherapy drug pembrolizumab (Keytruda) changes immune-related genes and biomarkers in people with advanced solid tumors like head and neck cancer, triple-negative breast cancer, ovarian cancer, and melanoma. Researchers will analyze bloo…

This study tested a program to help cancer patients understand their fertility risks and get the right care. It included 434 women aged 15-55 with a new cancer diagnosis. The program aimed to connect them with specialists for pregnancy planning or fertility preservation based on …

This study tests a new way of organizing care for people aged 70 and older who have cancer (breast, lung, colorectal, or prostate) plus at least one other serious health condition. The GERONTE program brings all their doctors and nurses together using a shared digital care plan. …

This study involves 400 men with high-risk prostate cancer who have not yet received treatment. Researchers are using a special type of scan called PSMA PET to see if it can find cancer that has spread to lymph nodes or other parts of the body, which standard scans often miss. Th…

This study tests a web-based tool called REFLECT, designed to help adolescent and young adult cancer patients learn about fertility and genetic risks for future children. Sixteen participants who have had cancer care at Moffitt Cancer Center will use the tool and rate how easy an…

This study aimed to test a new device that rotates patients horizontally to take CT images for guiding radiation therapy in cancer patients. It was designed for adults with certain cancers, but the trial was withdrawn before enrolling anyone. The goal was to see if the images wer…

This study looks at survival rates for people with cancers like melanoma, breast, colon, and lung cancer using data from Russian cancer registries. It includes 100,000 people of any age. The goal is to understand survival trends to help improve cancer care, not to test a new trea…

This study, called PARADIGM, is not testing a new drug. Instead, it looks at whether analyzing DNA from a blood sample can tell doctors which standard treatment—like hormone therapy or chemotherapy—will work best for a patient with metastatic prostate cancer. Researchers will tak…

This study compares how a single bout of exercise changes immune cells and inflammation in cancer patients undergoing chemotherapy and in healthy people of the same age. Researchers will measure natural killer cells and other immune markers before and after exercise. The goal is …

This study looks at medical records of 50 cancer patients who say cannabis helped stop their tumor from growing or shrank it. Researchers want to see if there is real evidence behind these claims. The goal is to gather information, not to test a new treatment.

This study looks at whether a 12-week survivorship program for men with advanced prostate, kidney, bladder, testicular, or penile cancer can be successfully added to their regular follow-up care. Researchers will measure how feasible and acceptable the program is using questionna…

This study explores whether wearable devices, like smartwatches, can help monitor symptoms in cancer survivors. Twenty participants will wear a sensor-packed device that tracks temperature, heart rate, sleep, and activity. Researchers will see how many people agree to use the wea…

This study looks at whether the standard blood test given to pregnant women to screen for fetal conditions can also detect signs of cancer in the mother. Researchers will analyze DNA from 300 pregnant women with known or newly diagnosed cancer to identify specific chromosomal pat…

This study looks at whether training and support can help cancer clinics give special check-ups (called geriatric assessments) to patients aged 65 and older who are starting a new cancer treatment. These check-ups help find and address health issues, support needs, and daily life…

This study compares a new total body PET scanner (Omni TB) with conventional PET in 25 adult cancer patients. The new scanner can image the whole body at once with higher sensitivity, potentially allowing shorter scan times and lower radiation doses. Researchers will assess wheth…

This study follows 304 men in Martinique diagnosed with prostate cancer from 2020 onward. Researchers use digital questionnaires to track changes in quality of life, especially sexual and urinary issues. The goal is to gather data to improve care and reduce health gaps in the Car…

This study follows 200 men with prostate cancer who are receiving hormone therapy (androgen deprivation therapy) for at least 6 months. Researchers want to understand how this treatment affects the heart over time, and how factors like medical history, race, income, and access to…

This study tests whether a wearable skin sensor can tell the difference between mild, moderate, and severe pain in 37 adults with cancer or COPD. Participants wear the device for up to a week and report their pain levels. The goal is to create an algorithm that alerts caregivers …

This study collects tumor tissue, blood, and saliva from 2500 people with various solid cancers to analyze their genetic makeup. The goal is to understand why some tumors become resistant to targeted therapies. Samples may also be grown in special mice to study how genetics affec…

This study looks at how older adults (65+) with cancer understand their illness and what they value in life before and after a major operation. Researchers will interview 100 patients to learn about their awareness, expectations, and decision-making. No new drug or treatment is b…

This study follows 178 patients who previously received an AvenCell CAR-T cell therapy for cancers like lymphoma, leukemia, or prostate cancer. Researchers will track delayed side effects, including new cancers or autoimmune issues, for years. No new treatment is given—this is pu…

This study tests a new lab method called OPTin that helps doctors pick the most effective drugs for people with advanced or hard-to-treat solid tumors. About 200 adults will provide a small tumor sample for testing, then receive either a drug chosen by OPTin or one selected by th…

This study is collecting blood, saliva, and health information from 2,100 Black and White cancer patients who are receiving immunotherapy (drugs that help the immune system fight cancer). The goal is to see if there are differences in side effects and how well the treatment works…

This study looks at whether combining genetic tests, regular drug level checks, and careful medication reviews can help doctors prescribe the right drugs and avoid harmful side effects. It involves 450 adults with cancer and children with chronic inflammatory diseases. The goal i…

This study checks how well a new MRI-guided radiotherapy machine works and how it fits into daily hospital routines. About 150 adults with solid tumors will take part. The goal is to see if the machine can be used smoothly for treatment, not to test a new cure.

This study is testing a new radiation technique that uses real-time MRI scans to target cancer more precisely. About 377 adult cancer patients will receive this treatment and have extra scans and quality-of-life surveys. The goal is to see if this approach improves tumor control …

This pilot study tests whether a smartphone app called Prostate Cancer Genius can help African American men learn about prostate cancer and complete a home-based PSA test. Eighty men aged 55 to 69 from Oklahoma who haven't had a PSA test in two years will use either the new app o…

This study looks at whether the Decipher test, which predicts how aggressive prostate cancer is, works the same for African-American men as for other men. The test was developed mainly from samples of European men, but African-American men have higher rates of prostate cancer and…

This study looks at whether it's possible to track memory and thinking changes in adults aged 65 and older who are starting a new type of cancer treatment called immune checkpoint inhibitors. Thirty participants will take simple memory and concentration tests every six weeks for …

This study was designed to test whether using smaller or larger stitches during robotic prostate surgery helps men regain bladder control faster. It planned to enroll men with prostate cancer undergoing robotic prostate removal. However, the trial was withdrawn before any partici…

This study looks at how certain hormone therapies for prostate cancer affect the heart. It compares two drugs, leuprolide and relugolix, given alongside radiation. The goal is to understand why some men develop heart problems and find ways to predict and reduce that risk. About 9…

This study looks at new ways to predict how prostate cancer and nearby healthy tissues react to a precise type of radiation therapy called SBRT. Researchers will analyze breath samples, blood DNA, and CT scans from 60 men with low- or intermediate-risk prostate cancer. The goal i…

This study looks at the stroma—the supportive tissue around tumors—in both benign and malignant growths. Researchers will examine 7,000 patient samples collected since 2000 at Brest University Hospital. The goal is to count non-tumor cells and measure matrix percentages in tumor …

This study looks at how doctors and nurses in radiation oncology used telehealth instead of in-person visits during the COVID-19 pandemic. Researchers will survey 1,000 healthcare providers at Duke Cancer Center to understand their experiences and challenges. They will also track…

This study tests a method called KIM that tracks the prostate's position during radiation using implanted gold markers. If the prostate moves more than 3mm, the radiation beam stops and is repositioned. The goal is to see if this technique is feasible in 100 men receiving radiati…

This study tests whether an educational video can help adults with serious cancer understand and use palliative care. 172 participants will either receive standard care plus brochures, or standard care plus a tailored video and extra materials. Researchers will track knowledge, a…

This observational study aims to create a national registry of genetic mutations found in advanced solid tumors. By collecting data from over 2,000 Italian patients, researchers hope to improve access to innovative therapies. The study does not test a new treatment but gathers in…

This study follows over 96,000 Seventh-day Adventists in the U.S. and Canada to see how diet and lifestyle choices relate to breast, colorectal, and prostate cancer. Researchers are focusing on intakes of meat, soy, and dairy. Because it is observational, it can show patterns but…

This observational study looks at why hormone therapy eventually stops working in advanced prostate cancer. Researchers will take tumor samples from 30 patients before and during treatment to study changes in immune cells and cancer markers. The goal is to find early signs of res…

This study was designed to look back at medical records of people in Picardy, France, who were diagnosed with both lymphoma and another cancer within six months between 2007 and 2012. The goal was to see if these cases were more common than expected and to describe patient charac…

This study looks at whether removing lymph nodes during prostate cancer surgery helps prevent the cancer from coming back in men with intermediate-risk prostate cancer. Currently, the procedure is standard but can cause side effects like swelling, blood clots, or nerve injury. Th…

This study looks at how the COVID-19 pandemic changed the number of new cancer cases in Bavaria, Germany. Researchers analyzed data from 438,000 adults diagnosed with cancer between 2018 and 2023 to see if certain regions or cancer types were more affected. The goal is to underst…

This study looks at financial problems (called 'financial toxicity') in young adults aged 18-39 who have finished cancer treatment. Researchers will survey 300 participants to measure money stress during and after therapy, and find out what factors make it worse. The goal is to l…

This study is looking at how things like diet, physical activity, and other lifestyle habits might affect a man's risk of getting prostate cancer. Researchers are studying more than 2000 men who are at higher risk to find biological markers in the blood that could help predict ri…

This study looks at how mind-body therapies—like mindfulness, laughter yoga, and art therapy—affect the quality of life and emotional distress of 150 cancer patients. Participants will fill out questionnaires before and after an 8-week program. The goal is to see if these therapi…

This study aims to see how prostate tumors change on MRI scans shortly after a precise type of radiation therapy (SBRT). Researchers will compare these MRI changes with PSA levels in the blood. The study involves 28 men with localized prostate cancer and is designed to improve un…

This study uses stem cells made from patients' own cells to understand why some people develop severe heart or lung side effects from certain chemotherapy drugs. Researchers will compare cells from patients who had extreme toxicity to those who did not. The goal is to uncover the…

This study explores whether advanced MRI scans can detect early changes in prostate tumors and nearby healthy tissues during radiation therapy. By spotting these changes sooner, doctors might adjust treatment to improve effectiveness and reduce side effects. The study involves 38…

This study is testing an online questionnaire called CHAMP that older adults with cancer can fill out before their doctor's visit. The tool asks about daily function, memory, mood, and support to help doctors tailor cancer treatment. Researchers want to see if the tool is easy to…

This study looks at whether certain inherited gene changes (EGFR mutations) increase the risk of lung cancer, especially in people who never smoked. Researchers collect saliva from cancer patients with a specific tumor mutation (T790M) to find these inherited changes. They also o…

This study analyzes medical records and biopsy samples from 3,350 men diagnosed with localized prostate cancer between 1990 and 2006. The goal is to identify biological, pathological, and clinical markers that can predict how the disease will progress. By understanding these fact…

This study looks at how the diversity of bacteria in the gut might affect how well immunotherapy works in people with solid tumors. Researchers will collect stool and blood samples from 70 cancer patients starting immunotherapy to track changes in gut bacteria and immune markers.…

This study looks at whether a special type of MRI, called RSI-MRI, can predict how well prostate cancer responds to radiation and hormone therapy. About 100 men with high-risk, localized prostate cancer will get this MRI before and during treatment. The goal is to see if the scan…

This study looks at how well cancer patients respond to common vaccines like flu, COVID-19, and shingles. Researchers will measure antibody levels before and after vaccination in 250 adults with cancer. The goal is to understand immune responses in this group, not to test a new t…

This study looks at whether a 2-minute animated video can help men with early-stage prostate cancer better understand their treatment options. About 400 men will watch the video and then choose between active surveillance, focal therapy, or standard treatments. Researchers will t…

This observational study follows 170 men with metastatic hormone-sensitive prostate cancer who are taking apalutamide as part of their standard care. Researchers will measure PSA levels and use questionnaires to assess fatigue, thinking skills, and quality of life over two years.…